Map Home
Type / to search with text or keywords
/
keyboard shortcut: Type "/" on your keyboard for a quick search
Search button
Loading...
Loading...
Scroll left
Grants
Citations
H-Index
Patents
News
Books
Scroll right
Collapse sidebar
Data issues & feedback
Adjust height of sidebar
KMap
People
Adjust height of sidebar
KMap
Profile
Brianna Denton
Manager, Regulatory
Cancer Center Division
Overview
Research
More
Collaboration
(30)
Bryan Clines
Mutual work: 2 Grants﹒2 Proposals﹒1 Supervisor
Collaboration Details
Carolyn Lane
Mutual work: 2 Grants﹒3 Proposals
Collaboration Details
Hina Arif Tiwari
Mutual work: 3 Grants﹒3 Proposals
Collaboration Details
Rachna Shroff
Mutual work: 5 Grants﹒6 Proposals
Collaboration Details
Alejandro Recio Boiles
Mutual work: 1 Grant
Collaboration Details
Page 1 of 6
Previous page
Next page
Grants
(13)
A Phase 1b Study of the OxPhos Inhibitor ME-344 Combined With Bevacizumab in Previously Treated Metastatic Colorectal Cancer
Active
·
2024
·
$0 / $502.8K
·
External
undefined (CD)
cancer,
metastasis,
drug combination,
treatment,
clinical trial
A First In Human Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-319 in B-cell Malignancies
Active
·
2023
·
$0 / $2.1M
·
External
undefined (CD)
clinical trials,
oncology,
pharmacokinetics,
safety,
efficacy
A Phase 2a, Double-Blind, Placebo-Controlled, Multi-Center, Randomized Study Evaluating LSTA1 when Added to Standard of Care (SOC) Versus Standard of Care Alone in Subjects with Advanced Solid Tumors
Active
·
2023
·
$0 / $825.5K
·
External
undefined (CD)
oncology,
clinical trials,
immunotherapy,
cancer treatment,
drug efficacy
A Phase 1, Open-Label, Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects with Advanced Solid Tumors and Subsequent Expansio
Active
·
2023
·
$0 / $735.4K
·
External
undefined (CD)
cancer,
pharmacokinetics,
clinical effects,
intravenous administration,
safety
Randomized Phase 2 Study of DKN-01 Plus FOLFIRI/FOLFOX and Bevacizumab Versus FOLFIRI/FOLFOX and Bevacizumab as Second-line Treatment of Advanced Colorectal Cancer (DeFianCe)
Active
·
2023
·
$0 / $568.2K
·
External
undefined (CD)
colorectal cancer,
treatment,
clinical trial,
dkn-01,
chemotherapy
Page 1 of 3
Previous page
Next page